Sat 24 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen | Ongoing | Interferon beta-1a | 3 | 105MS306 | KFSH&RC-J |
| An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Bristol-Myers Squibb | Terminated | NIVOLUMAB IPILIMUMAB | 3 | CA209-227 | KFSH & RC-R |
| An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients | Alcon | Completed | Travoprost 0.004% | 1 | C-12-009 | KKESH |
| "An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). " | Alexion | Completed | Asfotase Alfa | 2 | ENB-010-10 | KFSH & RC-R |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. | Novartis | Completed | Everolimus | 3b | CRAD001K24133 | KFSH & RC-R |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) | AbbVie | Ongoing | ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV) | 3b | M14-423 | KKUH |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | Albireo | Ongoing | A4250 | 3 | A4250-008 | KFSH&RC-R |
| "An open-label extension study of the long-term safety, tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." | GSK | Completed | Ambrisentan | 3 | 116457 | KFMC |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT | Roche | Completed | Atezolizumab (MPDL3280A; RO5541267) | 3 | MO29983 | KFSH & RC-R |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency | Synageva | Completed | Sebelipase alfa (SBC-102) | 2 | LAL-CL03 | KFSH & RC-R |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.